Recent Research Funding

Jad Z. Bou-Abdallah, MD.

“Our division's funding bolsters and propels clinical research,” says Jad Z. Bou-Abdallah, MD, who studies the impact of clopidogrel, an antiplatelet drug, on colonoscopies.

Our faculty and fellows conduct novel research backed by generous extramural and intramural funding.

Supported by grants from an assortment of sources, our physician-scientists are uniquely poised to embark on clinical, translational and basic research in a variety of areas.

We've received competitively awarded funding from sources including:

  • National Institutes of Health
  • Centers for Disease Control and Prevention 
  • U.S. Department of Veterans Affairs

Our division’s research has also received support from biotechnology and pharmaceutical companies. 

Our funded research efforts include:

Andrew Talal, MD, MPH

  • Best practice model to screen for Hepatitis C and HIV. Andrew Talal (Co-Investigator), Joshua Lynch (Co-Investigator). Gilead Sciences. $315,000. 11/1/2018-9/1/2019.
  • Patient-Centered HCV Care via Telemedicine for Individuals on Opiate Substitution Therapy: A Stepped Wedge Cluster Randomized Controlled Trial. Andrew Talal (Principal Investigator). Patient-Centered Outcomes Research Institute (PCORI). $7,000,000. 11/1/2016-10/1/2021.
  • TLR5 Agonist Entolimod as Immunotherapy for Liver Cancer and Hepatitis B Virus Infection. Andrew Talal (Co-Principal Investigator). The V Foundation for Cancer Research. $399,716. 11/1/2016-10/1/2018.
  • Pharmacokinetics of Methadone in HIV/HCV Infected Patients with and without Liver Fibrosis. Andrew Talal (Co-Investigator). NIH/NIDA. $94,532. 7/1/2016-6/1/2017.
  • An Exploratory Study to Evaluate the Kinetics of Viral Load Decline with Ombitasavir/AVT-450/Ritonavir and Dasabuvir Therapy with Low-Dose Ribavirin (RBV), Full Dose RBV or RBV Add-on in Treatment-Naïve Adults with Genotype 1a Chronic Hepatitis C Virus. Andrew Talal (Principal Investigator). Abbvie Pharmaceuticals. 6/1/2015-6/1/2017.
  • HIV/AIDS Clinical Trials Unit. Andrew Talal (Co-Investigator). ACTG sponsored by the National Institute of Allergy and Infectious Disease (NIAID) (University of Rochester). 12/1/2013-4/1/2021.